DALCOTIDINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C18H29N3O2
Molecular Weight	319.4418
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCNC(=O)NCCCOC1=CC=CC(CN2CCCCC2)=C1

InChI

InChIKey=SVCQBXMFONNZHX-UHFFFAOYSA-N

InChI=1S/C18H29N3O2/c1-2-19-18(22)20-10-7-13-23-17-9-6-8-16(14-17)15-21-11-4-3-5-12-21/h6,8-9,14H,2-5,7,10-13,15H2,1H3,(H2,19,20,22)

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/8096132
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/8096133, http://www.ncbi.nlm.nih.gov/pubmed/8096134

Dalcotidine is a histamine H2 receptor antagonist that demonstrated potent gastric mucosal protective activity on acute gastric lesions and duodenal ulcers. Dalcotidine was discontinued in phase III of clinical trials in Japan.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H2 receptor 46 Target ID: P25021 Gene ID: 3274.0 Gene Symbol: HRH2 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/8096132	Antagonist 2778		0.04 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gastric ulcer 67 Sources: http://www.ncbi.nlm.nih.gov/pubmed/8096134	Primary		Phase III 656	Unknown Approved Use Unknown
Duodenal ulcer 42 Sources: http://www.ncbi.nlm.nih.gov/pubmed/8096134	Primary		Phase III 656	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

In rats: 10-50 mg/kg x 2/day

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

DALCOTIDINE

Official Name

English

dalcotidine [INN]

Common Name

English

DALCOTIDINE [JAN]

Common Name

English

1-ETHYL-3-(3-((.ALPHA.-PIPERIDINO-M-TOLYL)OXY)PROPYL)UREA

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29702